Li Zhijun, Yu Qiong, Lu Xiaozheng, Liu Yahui, Ji Bai
Department of Hepatobiliary and Pancreatic Surgery, the First Hospital, Jilin University, Changchun, China.
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
Wideochir Inne Tech Maloinwazyjne. 2021 Sep;16(3):455-471. doi: 10.5114/wiitm.2021.105377. Epub 2021 Apr 14.
Hepatocellular carcinoma (HCC) has been the second leading cause of cancer-related death in China. Radiofrequency ablation is a relatively novel treatment that may improve the treatment of HCC.
To evaluate and compare the efficacy and safety of radiofrequency ablation (RFA) versus laparoscopic liver resection (LLR) in the treatment of HCC.
We searched for relevant published studies in English (PubMed, Cochrane Library, EMBASE) and in Chinese (CBM, CNKI and Wanfang) from their inception until September 23, 2019. The quality of included studies was evaluated by the Newcastle-Ottawa Scale.
A total of 19 retrospective studies including 2038 patients were eligible for the meta-analysis. The results of the meta-analysis demonstrated that LLR was superior to RFA in terms of 3-year overall survival rate (OR = 0.62), 1 to 3-year disease-free survival rates (OR = 0.57; OR = 0.41, respectively) and local recurrence rates (OR = 2.71).
The meta-analysis demonstrates that laparoscopic liver resection should be preferred in tumors of size 3-5 cm, while for < 3 cm the long term results are equal.
肝细胞癌（HCC）一直是中国癌症相关死亡的第二大主要原因。射频消融是一种相对新颖的治疗方法，可能会改善HCC的治疗效果。
评估并比较射频消融（RFA）与腹腔镜肝切除术（LLR）治疗HCC的疗效和安全性。
我们检索了英文（PubMed、Cochrane图书馆、EMBASE）和中文（CBM、CNKI和万方）从创刊至2019年9月23日发表的相关研究。纳入研究的质量采用纽卡斯尔-渥太华量表进行评估。
共有19项回顾性研究（包括2038例患者）符合荟萃分析的条件。荟萃分析结果表明，在3年总生存率（OR = 0.62）、1至3年无病生存率（分别为OR = 0.57；OR = 0.41）和局部复发率（OR = 2.71）方面，LLR优于RFA。
荟萃分析表明，对于3 - 5厘米大小的肿瘤，应首选腹腔镜肝切除术，而对于小于3厘米的肿瘤，长期效果相当。
